Genesee Capital Advisors’s Elevance Health ELV Stock Holding History

Genesee Capital Advisors’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,376	Closed	-$716K	–	130
2024 Q3	$716K	Sell	1,376 -18	-1%	-$9.62K	0.34%	62
2024 Q2	$755K	Sell	1,394 -320	-19%	-$169K	0.37%	61
2024 Q1	$889K	Buy	1,714 +18	+1%	+$8.95K	0.49%	48
2023 Q4	$800K	Buy	1,696 +135	+9%	+$62.4K	0.49%	46
2023 Q3	$680K	Sell	1,561 -75	-5%	-$34K	0.49%	52
2023 Q2	$727K	Sell	1,636 -1,285	-44%	-$593K	0.5%	51
2023 Q1	$1.34M	Buy	2,921 +4	+0.1%	+$1.9K	0.95%	26
2022 Q4	$1.5M	Sell	2,917 -208	-7%	-$106K	1.11%	25
2022 Q3	$1.42M	Sell	3,125 -32	-1%	-$15.3K	1.08%	26
2022 Q2	$1.52M	Buy	+3,157	New	+$1.56M	1.06%	26

Other funds holding ELV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Genesee Capital Advisors's ELV Position: Q4 2024 in Review

Genesee Capital Advisors sold out of Elevance Health (ELV) in Q4 2024, closing a stake of 1,376 shares — an estimated $716K sold.

Genesee Capital Advisors first reported a position in ELV in Q2 2022 and held it in 10 quarters. The position peaked at $1.52M in Q2 2022. 1,602 funds tracked by Wall St. Rank hold ELV as of Q4 2024.

Genesee Capital Advisors reported no remaining Elevance Health position as of Q4 2024 after selling out during the quarter.
Genesee Capital Advisors sold 1,376 Elevance Health shares in Q4 2024, an estimated $716K.
Genesee Capital Advisors first reported a position in Elevance Health in Q2 2022 and held it in 10 quarters.
Genesee Capital Advisors's Elevance Health position peaked at $1.52M in Q2 2022.
1,602 funds tracked by Wall St. Rank held Elevance Health as of Q4 2024.

Based on Genesee Capital Advisors's 13F filing for Q4 2024, filed 22 Jan 2025.